NHS-Galleri Linked to Delays - Summary - MDSpire

NHS-Galleri Linked to Delays

Analysis of England’s multicancer early detection screening trial found modest, temporary diagnostic delays in participating regions, adding to concerns about health system effects and the evidence base for population-level blood-based cancer screening.

  • By

  • Andrea Surnit

  • June 4, 2026

  • 6 min

Share

Objective:

To evaluate the impact of participation in the NHS-Galleri trial on diagnostic delay rates for suspected head and neck, lung, and upper gastrointestinal cancers.

Key Findings:
  • Diagnostic delay rates increased from 29% to 30% in participating regions and decreased from 29% to 26% in nonparticipating regions during the first 6 months.
  • Participation in the trial was associated with an approximately 3-percentage-point increase in diagnostic delay rates.
  • The estimated increase in delayed referrals during the first year was 9,591.
  • Average time to diagnostic resolution increased by about 2 days in participating regions.
Interpretation:

Limitations:
  • Participating regions had greater socioeconomic deprivation and fewer healthcare staff than nonparticipating regions, raising the possibility of residual confounding.
  • Only 6 months of pretrial data were available to assess baseline trends.
  • The data could not distinguish between referrals that resulted in cancer diagnosis and those in which cancer was ruled out.
Conclusion:

Original Source(s)

NHS-Galleri Linked to Delays

  • by Andrea Surnit

  • June 4, 2026

Related Content

Indeterminate Thyroid Nodule Size May Predict RFA Success

In a functionally screened cohort, there was an 85% likelihood of being free of local treatment failure at 3 years, with outcomes favoring nodules smaller than 3 cm.

Chemoimmunotherapy Linked to HNSCC Response

Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.